Uveitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Uveitis Pipeline Drugs Market Report Overview
Uveitis symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye, and sensitivity to light. Treatment includes steroid eye drops, anti-inflammatory, and antibiotic or antiviral medication.
The Uveitis pipeline drugs market research report provides an analysis of the Uveitis drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects.
Key Targets of the Uveitis Pipeline Drugs Market
Some of the targets of the Uveitis pipeline drugs market are Tumor Necrosis Factor, Glucocorticoid Receptor, Cannabinoid Receptor 2, Myristoylated Alanine Rich C Kinase Substrate, Nuclear Factor Kappa B, Aryl Hydrocarbon Receptor, Cannabinoid Receptor 1, and Complement C5 among others.
Uveitis Pipeline Drugs Market, by Key Targets
For more insights on key targets, download a free report sample
Key Mechanisms of Action in the Uveitis Pipeline Drugs Market
The key mechanisms of action of the Uveitis pipeline drugs market are Tumor Necrosis Factor Inhibitor, Glucocorticoid Receptor Agonist, Cannabinoid Receptor 2 Agonist, Myristoylated Alanine Rich C Kinase Substrate Inhibitor, Nuclear Factor Kappa B Inhibitor, Aryl Hydrocarbon Receptor Agonist, Cannabinoid Receptor 1 Agonist, and Complement C5 Inhibitor among others.
Uveitis Pipeline Drugs Market, by Key Mechanisms of Action
For more insights on key mechanisms of action, download a free report sample
Key Routes of Administration in the Uveitis Pipeline Drugs Market
The routes of administration in the Uveitis pipeline drugs market are ophthalmic, topical, intravitreal, subcutaneous, intravenous, oral, intraocular, and inhalational among others.
Uveitis Pipeline Drugs Market, by Routes of Administration
For more insights on routes of administration, download a free report sample
Key Molecule Types in the Uveitis Pipeline Drugs Market
The molecule types in the Uveitis pipeline drugs market are Small Molecule, Monoclonal Antibody, Synthetic Peptide, Recombinant Protein, Gene Therapy, Fusion Protein, and Monoclonal Antibody Conjugated among others.
Uveitis Pipeline Drugs Market, by Molecule Types
For more insights on molecule type, download a free report sample
Key Companies in the Uveitis Pipeline Drugs Market
Some of the key companies in the Uveitis pipeline drugs market are BioMarck Pharmaceuticals Ltd, Avirmax Inc, Elasmogen Ltd, EyePoint Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, HanAll Biopharma Co Ltd, Palatin Technologies Inc, and Tarsius Pharma Ltd among others.
Uveitis Pipeline Drugs Market, by Companies
For more insights on companies, download a free report sample
Uveitis Pipeline Drugs Market Report Overview
Key Targets | Tumor Necrosis Factor, Glucocorticoid Receptor, Cannabinoid Receptor 2, Myristoylated Alanine Rich C Kinase Substrate, Nuclear Factor Kappa B, Aryl Hydrocarbon Receptor, Cannabinoid Receptor 1, and Complement C5 |
Key Mechanisms of Action | Tumor Necrosis Factor Inhibitor, Glucocorticoid Receptor Agonist, Cannabinoid Receptor 2 Agonist, Myristoylated Alanine Rich C Kinase Substrate Inhibitor, Nuclear Factor Kappa B Inhibitor, Aryl Hydrocarbon Receptor Agonist, Cannabinoid Receptor 1 Agonist, and Complement C5 Inhibitor |
Key Routes of Administration | Ophthalmic, Topical, Intravitreal, Subcutaneous, Intravenous, Oral, Intraocular, and Inhalational |
Key Molecule Types | Small Molecule, Monoclonal Antibody, Synthetic Peptide, Recombinant Protein, Gene Therapy, Fusion Protein, and Monoclonal Antibody Conjugated |
Key Companies | BioMarck Pharmaceuticals Ltd, Avirmax Inc, Elasmogen Ltd, EyePoint Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, HanAll Biopharma Co Ltd, Palatin Technologies Inc, and Tarsius Pharma Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Acelyrin Inc
Aciont Inc
Active Biotech AB
Aerie Pharmaceuticals Inc
Akari Therapeutics Plc
Aldeyra Therapeutics Inc
Alpine Immune Sciences Inc
Alvotech ehf
Amytrx Therapeutics Inc
Avirmax Inc
BioMarck Pharmaceuticals Ltd
BioNanoSim Ltd
Bonac Corp
Cellivery Therapeutics Inc
Celltrion Inc
Chugai Pharmaceutical Co Ltd
Dobecure SL
E&B Technologies LLC
Elasmogen Ltd
Enzo Biochem Inc
EyePoint Pharmaceuticals Inc
Eyevensys SAS
F. Hoffmann-La Roche Ltd
HanAll Biopharma Co Ltd
IACTA Pharmaceuticals Inc
iCELL Biotechnology Co Ltd
Inovio Pharmaceuticals Inc
Juvenescence UK Ltd
Kiora Pharmaceuticals Inc
Kodiak Sciences Inc
Kriya Therapeutics Inc
Kubota Vision Inc
MeiraGTx Holdings Plc
Mitotech SA
Naegis Pharmaceuticals Inc
NeuClone Pty Ltd
Novaliq GmbH
Novartis AG
Oculis SA
OKYO Pharma Ltd
OncoNOx ApS
ONL Therapeutics Inc
Orchid Pharma Ltd
OSE Immunotherapeutics SA
Oxular Ltd
Palatin Technologies Inc
Panag Pharma Inc
Parvus Therapeutics Inc
Pharmapraxis
Reven Holdings Inc
Revolo Biotherapeutics Ltd
RiniSight Inc
Ripple therapeutics Corp
SFA Therapeutics Inc
Shanghai Henlius Biotech Inc
Shennong Biotech Inc
Skye Bioscience Inc
Sol-Gel Technologies Ltd
Tarsius Pharma Ltd
Tianjin Pharmaceuticals Group Co Ltd
Topas Therapeutics GmbH
Valitor Inc
Vyome Therapeutics Inc
Worg Pharmaceuticals Hangzhou Co Ltd
Wuhan Healthgen Biotechnology Corp
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the Uveitis pipeline drugs market?
Some of the targets of the Uveitis pipeline drugs market are Tumor Necrosis Factor, Glucocorticoid Receptor, Cannabinoid Receptor 2, Myristoylated Alanine Rich C Kinase Substrate, Nuclear Factor Kappa B, Aryl Hydrocarbon Receptor, Cannabinoid Receptor 1, and Complement C5 among others.
-
What are the mechanisms of action of the Uveitis pipeline drugs market?
The key mechanism of action of the Uveitis pipeline drugs market are Tumor Necrosis Factor Inhibitor, Glucocorticoid Receptor Agonist, Cannabinoid Receptor 2 Agonist, Myristoylated Alanine Rich C Kinase Substrate Inhibitor, Nuclear Factor Kappa B Inhibitor, Aryl Hydrocarbon Receptor Agonist, Cannabinoid Receptor 1 Agonist, and Complement C5 Inhibitor.
-
What are the routes of administration in the Uveitis pipeline drugs market?
The routes of administration in the Uveitis pipeline drugs market are ophthalmic, topical, intravitreal, subcutaneous, intravenous, oral, intraocular, and inhalational among others.
-
What are the molecule types in the Uveitis pipeline drugs market?
The molecule types in the Uveitis pipeline drugs market are Small Molecule, Monoclonal Antibody, Synthetic Peptide, Recombinant Protein, Gene Therapy, Fusion Protein, and Monoclonal Antibody Conjugated.
-
Which are the key companies in the Uveitis pipeline drugs market?
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.